Could a female hormone boost exercise benefits in men?

NCT ID NCT07791394

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

Researchers at the University of Waterloo are testing whether estrogen, a hormone more common in women, changes how exercise affects blood sugar control, inflammation, and immune function in men. The study will enroll 24 sedentary, overweight men aged 18 to 35. Participants will take either an estrogen supplement or a placebo for two weeks while doing high-intensity interval training. Before and after the training, researchers will measure insulin sensitivity, glucose handling, and muscle metabolism through blood tests, fitness tests, and muscle biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
17beta-estradiol (estrogen) taken as a supplement alongside exercise training
What this could lead to
If estrogen boosts the benefits of exercise, it could point toward new ways to improve blood sugar control and reduce inflammation in people with insulin resistance.
What could go wrong
This is a small, early study in men only, so results may not apply to women or larger groups. Estrogen supplements can have side effects, and the trial may not show a clear effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biological males (with no previous hormonal supplementation). * Between the ages of 18-35 years old * Non-smokers * Sedentary individuals (i.e., engaging in intentional moderate-to-vigorous physical activity \<2x/week) * Body mass index 27-32 kg/m2 * Body fat % \> 22% Exclusion Criteria: 1. Any state that can impact the hormonal milieu (e.g., drug/hormonal supplementation related to health). 2. Usage of anti-inflammatory medications, \>1 glucose lowering medications, insulin, platelet inhibitors, anti-coagulant medications or simvastatin, beta-blockers, weight loss medications (Orlistat, Saxenda, Contrave, Ozempic) or any medications known to affect protein metabolism (i.e., corticosteroids). 3. Presence of cardiovascular, respiratory, metabolic, autoimmune or renal disease. 4. Presence of any condition that makes the participant unable to participate in physical activity as determined using the CSEP Get Active Questionnaire. 5. Presence of injury that restricts exercise performance. 6. VO2max \> 50th percentile for age. 7. Previous (within the last 2 months) or current use of ergogenic aids (i.e. creatine). 8. Previous or current use of weight loss medications, including liraglutide, semaglutide, orlistat, ozempic, etc. 9. History and/or diagnosis of blood clots or family history of blood clot disorders. 10. History of allergies or sensitivities to local anesthetic 11. Ophthalmic vascular disease 12. Classical migraines 13. History of thromboembolic disease 14. Consume 15 or more alcoholic drinks/week or 3 drinks per day 15. Bleeding disorders 16. Severe peripheral neuropathy 17. Muscular dystrophy 18. Prior bariatric surgery 19. Osteoporosis/osteopenia 20. Orthopaedic issues 21. Presence of GI disorders (i.e., Colitis, Crohns disease, Celiac disease) 22. Presence of liver disease or dysfunction (i.e., diagnosed NAFLD, NASH, cirrhosis, previous liver transplant) 23. History of cancer 24. Type 1 or 2 diabetes 25. Presence of renal disorders (creatinine \> 140) 26. Uncontrolled hypertension (\>140/90 mmHg) 27. History of allergies or sensitivities to estradiol or to any ingredient in the formulation or component of the container 28. History and/or diagnosis of blood clots or family history of blood clot disorders 29. Have an implantable electronic device 30. Medical psychiatric history of depression, bipolar, anxiety, suicidal ideation, etc. 31. Inherited clotting disorders 32. Chest pain or shortness of breath 33. Inflammatory disorders (e.g., inflammatory bowel disorder) 34. Significant weight loss in the 3-month period prior to the study (10% of total body weight) 35. Any kind of major surgery recently 36. Bleeding disorders 37. Active or history of thromboembolic disease (including confirmed venous thromboembolism) 38. Ophthalmic vascular disease 39. Classical migraines

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Waterloo

    Waterloo, Ontario, N2L 3G1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.